Trial Profile
Immunomonitoring study to find predictive immune-related markers of the responsiveness to the ipilimumab treatment in patient with metastatic melanoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 03 Nov 2017 New trial record